Date: 2014-10-30
Type of information: Collaboration agreement
Compound: Olysio® (simeprevir)
Company: Medivir (Sweden) Swedish county councils (Sweden)
Therapeutic area: Infectious diseases
Type agreement: collaboration
Action mechanism:
- direct-acting antiviral agent/protease inhibitor/RNA polymerase (NS5B) inhibitor. Simeprevir is a NS3/4A protease inhibitor jointly developed by Medivir and Janssen for the treatment of chronic hepatitis C in adult patients with compensated liver disease.
Disease: genotype 1 and hepatitis C
Details:
- • On October 30, 2014, Medivir announced that the company has entered into an agreement with Swedish county councils regarding the treatment of hepatitis C with Olysio® (simeprevir). The Dental and Pharmaceutical Benefits Agency (TLV) has concluded that treatment with Olysio® (simeprevir) is beneficial from a health economics viewpoint in the treatment of HCV genotypes 1 and 4 with METAVIR scores of F3-F4, irrespective of previous treatment. A risk-sharing agreement between Medivir and the Swedish county councils has been drawn up in parallel with TLV’s health economic evaluation. The agreement offers the county councils and Medivir an increased degree of predictability with regard to treatment costs and the use of Olysio®, in that the risk-sharing applies both in relation to treatment results and to the number of patients who will be treated.
- Joint county council recommendations related to the use of Olysio® will be designed by the New Pharmaceutical Product Therapies (NLT) group (a group within the Swedish Association of Local Authorities and Regions tasked with evaluating new pharmaceutical products and therapies). The NLT group will have a meeting October the 30th regarding a protocol for structured introduction of Olysio®.
Financial terms:
Latest news:
Is general: Yes
